1. Generics Bulletin
  2. >>Products
  3. >>Biosimilars

US Must Rethink Biologic Naming Suffix, Says IGBA

 
• By Dave Wallace

In the wake of a decision by Health Canada not to implement a suffix to non-proprietary names to distinguish biosimilars from their branded counterparts, the IGBA has urged the FDA to reconsider the US approach.

LightBulb
An Increasingly Isolated US Is Urged To Rethink Its Biologic Naming Approach • Source: Shutterstock

Citing a “growing global consensus” against the use of product-specific suffixes to non-proprietary names to distinguish biosimilar medicines from their brand biologic counterparts, the International Generic and Biosimilar medicines Association (IGBA) has called on the US Food and Drug Administration (FDA) to rethink its use of such a mechanism given its status as a “notable outlier”.

The call follows Health Canada’s recent decision to not add suffixes to non-proprietary names for biologics – including biosimilars –...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Biosimilars

More from Products

FTC’s Latest Effort To Dispute Improper Patent Listings Barely Made A Dent

 
• By Urtė Fultinavičiūtė

Trump’s FTC has carried on two legacies – trying to eliminate improper drug patent listings and making minimal impact on such efforts.

Amphastar Unveils Plans To Quadruple US Manufacturing

 
• By Dave Wallace

Amphastar has announced plans to quadruple its domestic production capacity over the next three to five years. The move plays into a growing trend towards US manufacturing localization, against the backdrop of potential pharmaceutical tariffs being mooted by the Trump administration.

Bio-Thera Matches Alvotech With US Golimumab Filing Acceptance

 
• By Dean Rudge

Bio-Thera is one step closer to launching a biosimilar to Johnson & Johnson’s Simponi in the US, following FDA acceptance of its BAT2506 proposed golimumab candidate.